RxDoctor Payments Data

Christopher Cutler, MD

Gastroenterology · Sandy, UTNPI 1437162013

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,331 of the $2,845 with a category attached, or 82.0%. 17 manufacturers reported payments, led by AbbVie at 51.0% of the total.

$2,845in general payments, 2019–2025

Across 181 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Fujifilm Healthcare Americas Corporation$383
  • Johnson & Johnson$352
  • Pfizer$201
  • Takeda Pharmaceuticals U.S.A., Inc.$144
  • Bristol Myers Squibb$76
  • plus $238 from 11 others

What the payments were for

  • Food & beverage$2,33182%
  • Education$1305%
  • Gifts$2258%
  • Other$1586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,845 in reported general payments places this provider in the 55th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$66,338
Medicare patients
287
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide49$38,200
Adalimumab-Fkjp(Cf) PenAdalimumab-Fkjp13$13,707
Omeprazole444$4,743
Mesalamine28$4,639
Dexlansoprazole DrDexlansoprazole14$3,212
Balsalazide Disodium17$3,166
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C31$2,428
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,145
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg90$1,942
Pantoprazole Sodium96$1,820
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl84$1,592
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$986
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl50$929
Rabeprazole Sodium11$783
Azathioprine12$782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,450$38,20049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →